LHC Group (NASDAQ:LHCG) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “LHC Group, Inc. is the preferred post-acute care partner for hospitals, physicians and families nationwide. From home health and hospice care to long-term acute care and community-based services, LHC delivers high-quality, cost-effective care that empowers patients to manage their health at home. Hospitals and health systems around the country have partnered with LHC Group to deliver patient-centered care in the home. “

Other equities research analysts have also recently issued reports about the company. BidaskClub cut LHC Group from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Barclays increased their price objective on LHC Group from $95.00 to $104.00 and gave the company an “equal weight” rating in a research report on Thursday, March 21st. UBS Group set a $133.00 target price on LHC Group and gave the stock a “buy” rating in a research report on Friday, May 10th. Jefferies Financial Group raised their target price on LHC Group from $125.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Finally, Royal Bank of Canada raised their target price on LHC Group to $130.00 and gave the stock an “outperform” rating in a research report on Monday, May 13th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $120.58.

LHC Group stock opened at $115.92 on Thursday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.57 and a current ratio of 1.57. LHC Group has a one year low of $80.60 and a one year high of $122.20. The firm has a market cap of $3.62 billion, a P/E ratio of 32.65, a price-to-earnings-growth ratio of 1.96 and a beta of 0.83.

LHC Group (NASDAQ:LHCG) last released its quarterly earnings data on Wednesday, May 8th. The health services provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.90 by $0.08. LHC Group had a return on equity of 8.43% and a net margin of 3.83%. The company had revenue of $502.59 million for the quarter, compared to analysts’ expectations of $511.16 million. As a group, equities analysts anticipate that LHC Group will post 4.3 EPS for the current fiscal year.

In other LHC Group news, CEO Keith G. Myers sold 5,164 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $108.75, for a total value of $561,585.00. Following the transaction, the chief executive officer now directly owns 96,315 shares of the company’s stock, valued at $10,474,256.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Keith G. Myers sold 11,558 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $108.83, for a total value of $1,257,857.14. Following the completion of the transaction, the chief executive officer now directly owns 96,315 shares in the company, valued at $10,481,961.45. The disclosure for this sale can be found here. Insiders sold 59,685 shares of company stock worth $6,750,989 over the last three months. Insiders own 5.20% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Citigroup Inc. lifted its position in shares of LHC Group by 265.2% during the 4th quarter. Citigroup Inc. now owns 4,386 shares of the health services provider’s stock valued at $412,000 after buying an additional 3,185 shares in the last quarter. Everence Capital Management Inc. lifted its position in shares of LHC Group by 43.6% during the 1st quarter. Everence Capital Management Inc. now owns 4,050 shares of the health services provider’s stock valued at $449,000 after buying an additional 1,230 shares in the last quarter. Campbell Newman Asset Management Inc. lifted its position in shares of LHC Group by 2.4% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 6,350 shares of the health services provider’s stock valued at $704,000 after buying an additional 151 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of LHC Group during the 4th quarter valued at about $695,000. Finally, Geode Capital Management LLC lifted its position in shares of LHC Group by 6.7% during the 4th quarter. Geode Capital Management LLC now owns 325,548 shares of the health services provider’s stock valued at $30,562,000 after buying an additional 20,482 shares in the last quarter. 91.42% of the stock is currently owned by hedge funds and other institutional investors.

About LHC Group

LHC Group, Inc provides post-acute health care services to patients through its home nursing agencies, hospices and long-term acute care hospitals. The company operates through the following business segments: Home Health Services, Hospice Services, Home & Community-Based Services, Facility-Based Services and Healthcare Innovations.

Featured Story: Gap Up Stocks

Get a free copy of the Zacks research report on LHC Group (LHCG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.